These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35219075)

  • 1. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.
    Chen S; Zhao Y; Liu S; Zhang J; Assaraf YG; Cui W; Wang L
    Drug Resist Updat; 2022 Mar; 61():100821. PubMed ID: 35219075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
    Cao X; Hou J; An Q; Assaraf YG; Wang X
    Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.
    Guo L; Lee YT; Zhou Y; Huang Y
    Semin Cancer Biol; 2022 Aug; 83():487-502. PubMed ID: 33421619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA mediated drug resistance in breast cancer.
    Singh D; Assaraf YG; Gacche RN
    Drug Resist Updat; 2022 Jul; 63():100851. PubMed ID: 35810716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms.
    Mora Y; Reyes ME; Zanella L; Mora B; Buchegger K; Ili C; Brebi P
    Pharmacogenomics; 2021 Aug; 22(12):777-790. PubMed ID: 34281355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms.
    To KKW; Cho WCS
    Curr Cancer Drug Targets; 2021; 21(4):289-305. PubMed ID: 33535954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
    Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E
    Drug Resist Updat; 2011 Dec; 14(6):280-96. PubMed ID: 21955833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance.
    Fatma H; Maurya SK; Siddique HR
    Semin Cancer Biol; 2022 Aug; 83():166-176. PubMed ID: 33220458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.
    Wang Y; Huang Z; Li B; Liu L; Huang C
    Front Endocrinol (Lausanne); 2022; 13():863541. PubMed ID: 35620395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polytherapy and Targeted Cancer Drug Resistance.
    Chatterjee N; Bivona TG
    Trends Cancer; 2019 Mar; 5(3):170-182. PubMed ID: 30898264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bitter side of epigenetics: variability and resistance to chemotherapy.
    Hajji N; García-Domínguez DJ; Hontecillas-Prieto L; O'Neill K; de Álava E; Syed N
    Epigenomics; 2021 Mar; 13(5):397-403. PubMed ID: 29932342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.
    Rauscher S; Greil R; Geisberger R
    Curr Cancer Drug Targets; 2021; 21(4):353-359. PubMed ID: 33423645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cell epigenetics and chemoresistance.
    Crea F; Danesi R; Farrar WL
    Epigenomics; 2009 Oct; 1(1):63-79. PubMed ID: 22122637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
    Bourguignon LYW; Earle C; Shiina M
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
    Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.